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Abstract 
Background: Pregnancy-associated malaria (PAM) constitutes one of the most severe forms of malaria infection lead-
ing to fetal growth restriction and high risk of infant death. The severity of the pathology is largely attributed to the 
recruitment of monocytes and macrophages in the placenta which is evidenced by dysregulated inflammation found 
in placental blood. Importantly, CD36+ monocytes/macrophages are also thought to participate in the tight control 
of the pro- and anti-inflammatory responses following Plasmodium detection through elimination of apoptotic cells 
and malaria-infected erythrocytes, internalization and recycling of oxidized forms of low-density lipoprotein and 
collaboration with TLR2 in pro-inflammatory response. Interestingly, previous work demonstrated that CD36 expres-
sion was upregulated on inflammatory macrophages following stimulation of the Nrf2 transcription factor, whilst the 
PPARγ pathway was inhibited and non-functional in the same inflammatory conditions. This current study examined 
the possible role of Nrf2-driven gene expression, CD36 and Haem-Oxygenase-1 (HO-1), in PAM clinical outcomes.
Methods: Clinical data and biological samples including peripheral blood mononuclear cells were collected from 27 
women presenting PAM. Polychromatic flow cytometry was used to characterize innate immune cell subpopulations 
and quantify CD36 protein expression level on monocytes. mRNA levels of CD36, PPARγ, Nrf2 and HO-1 were deter-
mined by qPCR and related to clinical outcomes. Finally, the capacity of monocytes to modulate CD36 expression 
upon rosiglitazone or sulforaphane treatment, two respective PPARγ or Nrf2 activators, was also investigated.
Results: The CD36 receptor, mostly expressed by CD14+ circulating monocytes, statistically correlated with increased 
infant birth weights. Interestingly, mRNA levels of the transcription factor Nrf2 and the enzyme HO-1 also correlated 
with lower parasitaemia and increased infant birth weight, while PPARγ mRNA levels did not. Finally, monocytes 
isolated from low infant birth weight pregnant women were capable of up-regulating CD36 via the Nrf2 pathway 
ex vivo.
Conclusions: Altogether these results suggest that Nrf2-driven CD36 and HO-1 expression on innate immune cells 
could contribute to a protective and detoxifying mechanism during PAM. More powered and mechanistical studies 
are however needed to strengthen the conclusions of this study.
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Background
Each year, more than 125 million pregnant women are 
at risk of pregnancy-associated malaria (PAM), a severe 
form of malaria infection that affects both mothers and 
infants, causing maternal anaemia, pre-term delivery, 
fetal growth restriction and a higher risk of infant death 
[1, 2]. The severity of the pathology is attributed to the 
sequestration of Plasmodium falciparum-infected eryth-
rocytes (Pf-iE) in placental intervillous blood spaces that 
leads to the recruitment of monocytes and macrophages 
to the placenta [3, 4]. Several studies have demonstrated 
a link between monocyte/macrophage recruitment and 
adverse outcomes such as low birth weight and mater-
nal anaemia, but also functional damage to placental villi 
and disturbances to feto-maternal exchanges [4–7]. The 
mechanisms proposed imply monocyte/macrophage 
activation which is evidenced by high levels of pro-
inflammatory cytokines in placental blood [8–11].
On the other hand, it is largely accepted that mono-
cyte and macrophage infiltrates might also have a ben-
eficial role in defence mechanisms, such as non-opsonic 
CD36-dependent phagocytosis, antibody-dependent 
cellular inhibition (ADCI), opsonic phagocytosis and 
the production of cytokines that direct both cellular and 
humoral immunity [12, 13]. CD36, a membrane glyco-
protein present on many mammalian cells types, includ-
ing monocyte/macrophages, is a multifaceted receptor 
that displays an impressive range of functions [reviewed 
in 14]. On monocyte/macrophages, CD36 acts as a scav-
enger receptor to protect the host from inflammation 
through phagocytosis of apoptotic cells (efferocytosis) 
and diverse pathogens including Pf-iE. The initial sens-
ing of the invading malaria parasite is mediated through 
recognition of highly conserved microbial structures 
by pattern-recognition receptors (PRRs) expressed on 
monocytes and macrophages [12, 15]. The CD36 scav-
enger receptor, a PRR, is known for its involvement in 
recognizing and internalizing non-opsonized Pf-iE, in 
a non pro-inflammatory manner. Indeed, macrophages 
from CD36 knock-out mice were shown to engulf signifi-
cantly less iEs than macrophages from CD36 wild-type 
mice, and displayed earlier peaks of parasitaemia, higher 
parasite densities and mortality rates [16–18]. CD36 also 
contributes in the internalization and the recycling of 
oxidized forms of low-density lipoprotein (oxLDL) [14]. 
In complement with its phagocytic activities, CD36 is 
also known to contribute to the regulation of the inflam-
matory response through cooperation with TLR2 [19]. 
CD36 and TLR2 collaboration leads to a pro-inflam-
matory response via ERK, p38, MAPK, JNK and NF-kB 
signaling following interaction with malaria-GPI anchors 
[19, 20]. On endothelial cells, CD36 is known for its role 
as a negative regulator of angiogenesis and has also been 
identified as a sequestration receptor for Pf-iE during 
malaria [21], although the main sequestration receptor 
during PAM is chondroitin sulfate A (CSA) [22]. Even 
though P. falciparum parasites infecting pregnant women 
are known to predominantly display CSA-adherent phe-
notype and low adhesion to CD36 [23], the multifaceted 
roles of CD36 have prompted us to examine the possible 
involvement that this receptor may play in PAM clinical 
outcomes.
CD36 expression is under the transcriptional control 
of the peroxisome proliferator-activated receptor gamma 
(PPARγ) and the nuclear factor erythroid-derived 2-like 
2 (NF-E2L2 or Nrf2) [24, 25]. During malaria blood stage 
infection, haemoglobin metabolism by the parasite leads 
to reactive oxygen species (ROS) production that acti-
vates the transcription factors PPARγ and Nrf2 [26–28]. 
Importantly, it was demonstrated in vitro that human and 
murine macrophages downregulated CD36 expression 
in the presence of TNF, due to a failure to express and 
activate PPARγ [29]. However, unlike PPARγ agonists, 
Nrf2 activators maintained their capacity to enhance 
CD36 expression and CD36-mediated phagocytosis in 
inflammatory conditions [29]. During PAM, elevated 
pro-inflammatory cytokines are consistently found, par-
ticularly TNF, IFNγ and MCP-1 [8, 9], suggesting a pos-
sible impairment of the PPARγ pathway. Furthermore, 
the activation of the nuclear factor Nrf2 constitutes a 
key mechanism in the antioxidant defence response used 
by host cells during infection [30]. Among the hundreds 
of Nrf2-regulated genes, the enzyme haem oxygenase-1 
(HO-1) is certainly one of the most important and was 
identified as a crucial detoxifier of free haem during 
malaria infection [31]. The role of HO-1 during malaria 
is however controversial and requires a better under-
standing. The protective role of HO-1 and carbon mon-
oxide against cerebral malaria development in mice was 
previously demonstrated [32, 33], whereas other groups 
reported that high HO-1 was a risk factor for severe or 
cerebral malaria in African children [34, 35]. The detoxi-
fying function of HO-1 is also closely related to another 
scavenger receptor, CD163, that binds the haptoglobin–
haemoglobin complex, removes it from circulation by 
endocytosis, allowing subsequent degradation of haem 
by HO-1 [36]. Few reports have investigated CD163 as 
a biomarker during malaria, although it may constitute 
an important factor implied in the anti-inflammatory 
response.
To date, no study has demonstrated that monocytes/
macrophages can contribute to malaria protection dur-
ing pregnancy. Here, monocytes sampled from women 
presenting PAM at delivery in Benin (West Africa) 
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were studied. The objective was to examine whether the 
expression of both CD36 and HO-1 by monocytes plays 
a role in clinical outcomes during PAM, based on the fol-
lowing hypothesis: (1) the scavenger receptor CD36 may 
be involved in the pro- and anti-inflammatory response, 
and to a lesser extent the elimination of Pf-iE during 
PAM; and (2) in a PAM context, the Nrf2 pathway may 
play an important role, both for its maintenance of CD36 
expression and for its capacity to modulate the expres-
sion of detoxifying enzymes including HO-1. This study 
demonstrates that CD36 expression is directly correlated 
to higher infant birth weights. Furthermore, the impor-
tance of the Nrf2 pathway was also shown by an inverse 
relationship between Nrf2 mRNA levels and parasitae-
mia, and a positive correlation between HO-1 mRNA and 
a higher infant birth weight. Finally, CD36 expression on 
monocytes from mothers with low birth weights infants 
could be increased following Nrf2 stimulation, but not 
PPARγ. Altogether these results suggest that Nrf2-driven 
CD36 and HO-1 expression on innate immune cells 




Patient enrolment and ethical statement are described 
elsewhere [37]. Briefly, ethical clearance was obtained 
from the Institutional Ethics Committee of the Faculté 
des Sciences de la Santé at the Abomey Calavi Univer-
sity in Benin. Pregnant women were enrolled in Coto-
nou, southern Benin, in the Mother and Child Hospital 
(Hôpital de la Mère et de l’Enfant Lagune). Inclusion cri-
terion was a positive diagnosis for P. falciparum infection 
at delivery. Parasitaemia was retrospectively quantified 
through Giemsa-stained thick blood smears prepared 
from peripheral blood and through placental impression 
smears.
Clinical outcomes
Two clinical outcomes were studied: parasitaemia and 
infant birth weight. Both placental and peripheral para-
sitaemia were analysed, respectively named “P” and “pP”. 
As 1  % parasitaemia and 2500  g for infant birth weight 
(BW) are standard thresholds in clinical malaria studies, 
both thresholds were considered (P or pP >1 % and BW 
≤2500 g) to define adverse outcomes.
Blood sampling and PBMC isolation
Peripheral venous blood was collected from all patients 
in a vacutainer tube containing EDTA and processed 
within 4 h. Plasma was sampled after centrifugation and 
stored at −20 °C. Human peripheral blood mononuclear 
cells (PBMC) were isolated by a density gradient centrifu-
gation method on Lymphoprep (Abcys, France).
TNF and IL‑10 plasma titration
The levels of TNF and IL-10 in plasma samples were 
determined using a commercially available OptiEIA kit 
(BD Biosciences) as per manufacturer’s instructions.
Flow cytometric analysis
Peripheral blood mononuclear cells were stained with 
CD14-PerCp, CD16-FITC (Immunotech), and CD36-
APC (BD Pharmingen) antibodies during 15  min in the 
dark for monocyte identification. A minimum of 5000 
cells were analysed for each data point. Acquisitions 
were performed on a FACScalibur using CellQuestPro 
software (Becton Dickinson, France). Forward and side 
scattering parameters (FSC and SSC) were first used to 
gate on monocytes among other leucocytes. Three CD14 
CD16 monocytes subsets were defined according to anti-
CD14 and anti-CD16 labeling (see Fig. 1).
Monocyte activation and mRNA expression measurements 
by RT‑qPCR
Monocytes were isolated by adherence to plastic for 1 h 
30 min in M-SFM (Gibco Invitrogen) at 37 °C 5 % CO2. 
After several washes in pre-warmed PBS, monocytes 
were incubated during four additional hours in sepa-
rate wells with 1 µM rosiglitazone (Cayman Chemical), 
1  µM sulforaphane (Sigma Aldrich), or with medium 
alone (control wells). Cells were prepared for RNA 
extraction with the RNAqueous®-Micro Kit (Ambion, 
Life Technologies), as described by the supplier. Syn-
thesis of cDNA was performed from a minimum of 
100  ng of total RNA with Verso cDNA Synthesis Kit 
(Thermo Scientific) according to the manufacturer’s 
recommendations and primed with anchored oligo-dT. 
Quantitative real-time PCR was performed on a Light-
Cycler 480 system using LightCycler 480 SYBR Green I 
Master (Roche Diagnostics). Serially diluted samples of 
pooled cDNA were used as external standards in each 
run for the quantification and results were expressed 
in fold induction relative to the respective control. 
The amplifications were performed for 60 cycles (10  s 
at 95  °C and 60  s at 60  °C) but the numbers of cycles 
needed for amplification (Cp) for all the genes tested 
was between 15 (18S) and 35 (PPARγ). The primers (at 
a final concentration of 10  mM) were designed using 
Primer 3 software, and are listed in Additional file  1: 
Table S1. Human 18s mRNA was used as the invariant 
control.
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Statistical analysis
All statistical analyses were carried out with non-para-
metric tests and performed with the software Statview. 
The Wilcoxon rank test was used to compare the distribu-
tion of continuous values. Values were compared accord-
ing to categorized variables (birth weight, parasitaemia, 
clinical outcome, plasma TNF and IL-10 levels, CD36 
protein expression level) by Mann–Whitney U-test, two-
factor covariance analysis (ANOVA) and Kruskal–Wallis 
test. The Spearman correlation test was used to test the 
relation between continuous variables.
Results
Clinical, parasitological and biological data
Table  1 represents general clinical and parasitological 
data obtained from the pregnant women included in the 
study. Low birth weight was neither associated with age, 
gravidity, parasitaemia, nor cytokine levels. Women that 
displayed a peripheral parasitaemia ≥1  % were younger 
with a lower gravidity, higher prevalence of placental 
parasitaemia and increased IL-10 plasma levels. Pla-
cental parasitaemia was overall higher than peripheral 
parasitaemia (Wilcoxon rank test, P = 0.02). No adverse 
Fig. 1 Relations between PAM, monocyte sub-populations and CD36 expression. a Gating strategy for the identification of monocyte sub-popu-
lations. Forward and side scattering parameters (FSC and SSC) were first used to gate monocytes among other leucocytes. Monocytes were sub-
divided into CD14+ CD16−/CD14+ CD16+/CD14low CD16+, according to CD14 and CD16 staining characteristics. Plots shown are representative 
examples. b Percentages of each monocyte sub-set found in PAM monocytes. c CD36 protein expression according to monocyte sub-populations 
in PAM. Geometric mean fluorescence intensity (MFI) was measured by flow cytometry for each monocyte sub-set. Values were compared by the 
Mann–Whitney U-test
Table 1 Clinical, parasitological and plasma cytokine levels of pregnant women
Data are presented in medians (interquartile range)
Data were compared according to the clinical criteria defined (BW ≤2.5 kg versus BW >2.5 kg, P <1 % versus P ≥1 %, pP <1 % versus pP ≥1 %) by Mann–Whitney 
U-test
P peripheral parasitaemia, pP placental parasitaemia
* P < 0.05, ** P < 0.005, *** P < 0.0005
All (N = 25) BW ≤2.5 kg (N = 5) P ≥1 % (N = 8) pP ≥1 % (N = 10)
Age (years) 25 (22–30) 25 (21–37) 22 (20–23)** 23 (22–27)
Gravidity 2.0 (2.0–3.5) 2.0 (2.0–6.0) 2.0 (1.0–2.0)* 2.0 (1.0–3.0)
Birth weight (kg) 2.8 (2.5–3.1) 2.0 (1.7–2.2)** 2.8 (2.6–3.2) 2.9 (2.8–3.4)
P (%) 0.05 (0.01–3.5) 0.03 (0.02–2.9) 6.0 (4.1–10.8)*** 2.2 (0.03–8.7)
pP (%) 1.0 (0.07–13.5) 0.1 (0.06–12.4) 28.0 (3.7–59.0)* 21.5 (10.0–63.0)***
TNF (pg/mL) 0 (0–0.8) 0 (0–12.2) 0 (0–0.1) 0 (0–0.6)
IL-10 (pg/mL) 0 (0–186) 111 (14–226) 628 (506–891)*** 308 (12–732)
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outcome was reported in the group of pregnant women 
following delivery, apart from the low birth weight.
CD14 CD16 monocyte sub‑populations differ by their 
levels of CD36 protein expression
Human monocytes were classified based on CD14 and 
CD16 expression in a major classical sub-population 
(CD14+ CD16−), and two minor sub-populations, inter-
mediate (CD14+ CD16+) and non-classical monocytes 
(CD14low CD16+) [38]. Polychromatic flow cytometry 
analysis was used to precisely identify the monocyte 
subsets based on CD14 and CD16, and determine their 
expression of CD36 (Fig.  1a). The mean percentages 
(±SEM) of each monocyte subset was 56.8  % (±4.2) 
CD14+ CD16−, 23.5 % (±3.1) CD14+ CD16+ and 19.7 % 
(±3.2) CD14low CD16+ (Fig.  1b). As shown in Fig.  1c, 
CD36 protein expression was similar between the CD14+ 
CD16− and CD14+ CD16+ subsets but significantly 
reduced in CD14lowCD16+ monocytes (Mann–Whitney 
U-test, P < 0.0001).
CD36 mRNA and protein expression levels correlate 
with increased birth weight
To evaluate the implication of the CD36 receptor on 
circulating monocytes during PAM, the relationship 
between clinical parameters and its expression level was 
analysed. As the number of pregnant women included 
in the study was relatively low (n  =  27), it reduces the 
power of the statistical tests used. Thus, two complemen-
tary statistical approaches were used to consolidate the 
results, the two-factor covariance analysis (ANOVA) and 
the Spearman correlation test (see Fig.  2). High CD36 
protein expression levels statistically correlated with 
increased birth weight according to both tests (Fig. 2a, b, 
P ≤ 0.05). CD36 mRNA levels also positively correlated 
with infant birth weight by the Spearman test (Fig.  2d, 
P < 0.05, Fig. 2c, P > 0.05). No other significant relation-
ships were found with the other recorded clinical param-
eters. These results demonstrate that CD36 expression 
on monocytes was positively associated with an impor-
tant and favourable clinical outcome for PAM.
High Nrf2 and HO‑1 mRNA levels correlate with low 
parasite density and high infant birth weight
To further the analysis carried out on CD36, the study 
focused on the different transcription factors regulat-
ing CD36 expression on monocytes. The transcrip-
tional regulation of CD36 is known to involve both the 
PPARγ and Nrf2 transcription factors [24, 25]. HO-1 
mRNA levels were also examined, as its gene regulation 
directly depends upon Nrf2 activation. CD36, PPAR-γ, 
Nrf2 and HO-1 mRNA levels were all highly correlated 
with each other. Specifically, CD36 and PPAR-γ were 
strongly correlated with each other and Nrf2 and HO-1 
[P < 0.0001 by the Spearman test, correlation coefficient 
(rho)  =  0.71–0.84]. Nrf2 and HO-1 were similarly well 
correlated (P < 0.001, rho = 0.56) (Fig. 3). The potential 
link between these factors and various clinical features 
associated with PAM was investigated. Nrf2 mRNA lev-
els were higher in monocytes from pregnant women 
presenting peripheral or placental parasitaemia <1  % 
(Fig.  4a, b). Additionally, higher levels of HO-1 mRNA 
were linked with increased infant birth weight (Fig. 4c). 
No clinical features were found to be associated with 
PPARγ (see Fig.  4a, b). These results outline the poten-
tial beneficial role of the Nrf2/HO-1/CD36 axis on PAM 
clinical outcomes.
Nrf2 activation can restore CD36 levels in monocytes 
from mothers with low birth weight children
To assess the capacity of monocytes from PAM patients 
to modulate CD36, the mRNA level of CD36 upon 
rosiglitazone or sulforaphane treatment, two respective 
PPAR-γ and Nrf2 inducers, was measured. Furthermore, 
the level of gene induction was also compared between 
mothers who bore infants with low (MoLBW) and high 
(MoHBW) birth weights. Interestingly, MoLBW dis-
played significant increases in CD36 transcription fol-
lowing sulforaphane treatment compared to MoHBW 
(Fig. 5, Mann–Whitney U-test, P = 0.005). It is important 
to note here that the maximum level of CD36 mRNA did 
not differ between the two groups, and that the increase 
was due to a low basal level of CD36 in the MoLBW. 
Rosiglitazone treatment failed to induce CD36 mRNA 
induction in both groups of women.
CD36, Nrf2, PPARγ and HO‑1 mRNA levels were higly 
corelated to anti‑inflammatory markers IL‑10 and CD163
The relationship between anti-inflammatory markers and 
CD36 expression was examined, as well as PPARγ, Nrf2 
and HO-1. As shown in Fig. 6, CD36, PPARγ, Nrf2 and 
HO-1 mRNA levels were all positively correlated with 
IL-10 (Fig. 6a) and CD163 mRNA levels (Fig. 6b) (Spear-
man correlation test, P < 0.005 to P < 0.0001). CD163 and 
IL-10 were also highly related (Fig. 6a).
Discussion
Monocyte/macrophage accumulation in placental blood 
intervillous spaces during PAM is widely associated with 
poor clinical outcome [4–6]. The objective of this study 
was to examine the role of the monocyte/macrophage 
receptor CD36 and the detoxifying enzyme HO-1 during 
PAM. In this study, monocytes from Beninese pregnant 
women infected with malaria at delivery were stud-
ied. A total of 27 pregnant women were included in the 
study and subdivided into two groups based on the birth 
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weight of their infants. For the first time, a correlation 
between Nrf2-driven CD36 and HO-1 gene expression 
on circulating monocytes and a positive outcome during 
PAM was demonstrated on clinically relevant samples. 
While the low number of MoLBW (n = 5) is a limitation, 
the use of multiple and complementary statistical tests 
helps to validate and strengthen the findings. More statis-
tically powered studies will be needed to explore possible 
mechanisms.
Low infant birth weight constitutes one of the main 
adverse outcome for PAM, due to restricted growth dur-
ing pregnancy and to placental circulation disturbances 
[39], for which there are two non-excluding hypotheses. 
One is based on impaired uterine artery remodeling 
which leads to the release of pro-inflammatory cytokines 
that cause hemodynamic disturbances in the utero pla-
cental circulation [40]. The other is based on mechanical 
obstruction of the intervillous spaces due to infected 
erythrocytes and monocytes, and fibrin deposition [41]. 
The present report supports the second hypothesis, as 
the involvement of CD36 implicates the elimination of 
Pf-iE and apoptotic cells which would likely contribute to 
the removal of any obstructions in the intervillous spaces. 
However, the CD36 adhesion phenotype is not a com-
mon feature of malaria, as placenta-sequestered parasites 
are known to more strongly adhere to CSA as opposed 
to CD36 [22, 42]. CSA-binding isolates were indeed 
shown to present a defect for non opsonic phagocyto-
sis in vitro [43]. Importantly, placental pathology during 
malaria infection in mice has been reported to depend 
on a mitochondrial-dependent apoptotic pathway occur-
ring through increased lipid peroxidation thus jeopardiz-
ing the materno–fetal relationship [44]. Considering that 
CD36 plays an important role in the non-inflammatory 
Fig. 2 Relation between CD36 protein and mRNA expression and birth weight in PAM. a, c CD36 MFI and mRNA expression levels were compared 
according to birth weight threshold of 2.5 kg, by the two-factor covariance analysis (ANOVA). b, d CD36 MFI and mRNA expression levels were 
positively related to birth weight values by the Spearman correlation test
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elimination of apoptotic cells [14], it is tempting to spec-
ulate that CD36 may also regulate the elimination of dead 
cells at the placental level during PAM, which would 
maintain feto–maternal exchanges and increase birth 
weight at delivery.
The other known function of CD36 during malaria 
infection includes its collaboration with TLR2 to trig-
ger inflammatory response to Pf-GPI anchors [19]. This 
should logically not correlate to higher birth weights as 
the inflammatory response in the placenta is thought 
to lead to low birth weight by damages caused to the 
placenta villi and the disturbance of feto–maternal 
exchanges [6, 45]. In this study, birth weight was not 
related to cytokine levels, but an increase in IL-10 plasma 
levels was noticed in response to increased parasite den-
sities which is in line with previous literature proposing 
IL-10 as a biomarker of P. falciparum infection during 
pregnancy [46]. Production of IL-10 during PAM may 
help in counteracting the consecutive damages of the 
inflammatory response. In a longitudinal study compar-
ing uninfected and P. falciparum infected women dur-
ing pregnancy, the increase of IL-10 level during PAM 
Fig. 3 Correlations between CD36, PPARγ, Nrf2 and HO-1 mRNA levels expressed by monocytes sampled in Beninese women presenting malaria 
at delivery. a Correlations between CD36/PPARγ, CD36/Nrf2 and PPARγ/Nrf2. b Correlations between HO-1/CD36, HO-1/PPARγ and HO-1/Nrf2. 
Statistical significance was tested by the Spearman correlation test. ***P < 0.0005, **P < 0.005, *P < 0.5
Fig. 4 Influence of Nrf2, PPARγ and HO-1 mRNA levels on clinical parameters in PAM. Correlations between Nrf2 or PPARγmRNA levels were related 
to peripheral (a) and placental parasitaemia (b). c HO-1 mRNA level correlation to birth weight. Values were compared by the Mann–Whitney U-test
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was combined to increased IP-10 level and decreased 
RANTES level regardless of gestational age at the time of 
infection [47]. RANTES, a chemokine implied in leuco-
cyte recruitment at inflammatory sites, has been associ-
ated with severity and mortality in malaria children [48, 
49]. In addition, RANTES production was shown to be 
IL-10-dependent in vitro [50]. IP-10 has also been iden-
tified as a biomarker for mortality in children with cer-
ebral malaria [51] or severe malaria [52]. IL-10, IP-10 and 
RANTES are thus probably implied in the control of the 
pro- and anti-inflammatory balance, a key factor during 
PAM for limiting both infection and foetus damages.
Interestingly the CD36 scavenger receptor was strictly 
expressed by CD14+ CD16− and CD14+ CD16+ mono-
cytes, and its expression was extremely low in CD14low 
CD16+ monocytes. Intermediate monocytes (CD14+ 
CD16+) are thought to be largely anti-inflammatory by 
producing high levels of IL-10 and increasing phagocytic 
activity [53]. The overexpression of CD36 on these cells 
would contribute to the former, however CD36-depend-
ent phagocytosis may not be very relevant during PAM. 
On the other hand, CD36 and IL-10 mRNA levels in 
monocytes from this cohort were positively correlated, 
suggesting that CD36 expression was involved in an anti-
inflammatory process. The anti-inflammatory response 
during malaria also implies the receptor CD163 which 
scavenges the complex haemoglobin:haptoglobin, allows 
heme degradation by HO-1, avoids tissue damage [54, 
55], and facilitates IL-10 secretion [56].
The present work demonstrates a link between the 
transcription of CD36, CD163, HO-1 and IL-10 mRNA 
during PAM. CD36, Nrf2 and PPARγ were also related 
Fig. 5 Capacity of monocytes to modulate CD36 expression in PAM. 
Monocytes were treated with sulforaphane (10 µM) and rosiglitazone 
(5 µM), two respective agonists of Nrf2 and PPARγ for 4 h before the 
detection of CD36 mRNA level by qRT-PCR. Left panel Monocytes 
sampled in women with low infant birth weights (≤2.5 kg) produced 
higher levels of CD36 mRNA after sulforaphane activation than 
monocytes related to high infant birth weight (>2.5 kg). Right panel 
Activation of these two groups of monocytes with rosiglitazone did 
not lead to any difference. Monocytes activated by sulforaphane 
were also compared to monocytes activated by rosiglitazone. No dif-
ference of capacity to produce CD36 mRNA was found, whatever the 
group of monocytes. Values were compared by the Mann–Whitney 
U-test
Fig. 6 Correlations between CD36, PPARγ, Nrf2, HO-1 mRNA levels and IL-10 and CD163 mRNA levels expressed by monocytes sampled in Beni-
nese women presenting malaria at delivery. a Correlations to IL-10. b Correlations to CD163. Statistical significance was tested by the Spearman 
correlation test. ***P < 0.0005, **P < 0.005, *P < 0.5
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to CD163 expression, reinforcing the anti-inflamma-
tory aspect of CD36 expression on monocytes. Chua 
et  al. reported an association between the soluble form 
of CD163 (sCD163) and poor clinical outcomes dur-
ing PAM, i.e. lower hemoglobin levels and lower infant 
birth weights compared to uninfected pregnant women 
[57]. sCD163 is the result of CD163 shedding induced 
by TNF [36]. sCD163 levels were shown to be inversely 
correlated to membrane-bound CD163, suggesting that 
high sCD163 levels may reflect lower membrane-bound 
CD163 activity [58]. These results combined with the 
present study suggest that a greater activity of mem-
brane-bound CD163, or a higher expression of CD163 
on the cell surface, would promote favorable clinical 
outcomes during PAM by limiting inflammation due to 
free hemoglobin and heme. This possibility, however, 
deserves further investigation.
Non-classical (CD14low CD16+) monocytes are 
described as the pro-inflammatory monocytes producing 
TNF and little or no IL-10 [59]. Interestingly, a low CD36 
expression level was observed in these cells, which cor-
relates with previous findings demonstrating that inflam-
matory processes, including TNF stimulation, dampens 
CD36 expression through an inhibition of PPARγ tran-
scriptional activity [29]. These results support the notion 
that a CD14+ phenotype, tolerant to CD36 expression, 
are linked to beneficial outcomes during PAM. It can 
be also noted that CD14+ monocytes were largely pre-
dominant (80.3 %), despite a noteworthy increase of the 
non-classical monocyte population compared to healthy 
pregnancy (see Fig.  1b). CD36 expression may thus 
have a real impact even if its expression may be lowered 
compared to uninfected women. However, additional 
studies could help in understanding the sequence and 
interdependence of events such as Nrf2 activation, CD36 
expression on monocytes, HO-1 and CD163 induction, 
and IL-10 production during PAM.
PPAR-γ and Nrf2 transcription factors were both 
shown to regulate CD36 protein expression on mono-
cytes [24, 25]. Olagnier et al. demonstrated that in inflam-
matory conditions the stimulation of the Nrf2 pathway 
improved the outcome of severe malaria in mice, whereas 
PPARγ activation was only slightly active and much less 
efficient in inducing CD36 expression [29]. In addition, a 
previous report showed that circulating monocytes from 
malaria-infected patients presented decreased CD36 pro-
tein expression [60]. In this study, the capacity of circu-
lating monocytes from PAM patients to modulate CD36 
expression upon rosiglitazone or sulforaphane activation, 
two respective PPAR-γ and Nrf2 agonists, was evalu-
ated. Only sulforaphane activation induced monocytes 
from MoLBW to increase CD36 mRNA levels to those 
of MoHBW. This indicates that MoLBW do not have an 
impaired Nrf2 pathway, but likely lacked the appropriate 
stimulation in vivo. Nrf2 activators may be endogenous, 
particularly the products of oxidative stress (oxygen 
reactive species, lipid mediators), or exogenous, such as 
electrophile molecules (curcumin and sulforaphane for 
example). This result underlines the potential role of the 
Nrf2 pathway in limiting malaria severity during PAM.
Interestingly, this study showed that increased Nrf2 
mRNA levels were associated with lower peripheral and 
placental parasitaemia during PAM, whereas no such 
relation was found for PPAR-γ mRNA levels. Thus, it 
can be postulated that in this Beninese PAM context, the 
Nrf2 pathway, and not the PPAR-γ pathway, is associated 
with limited parasite survival and proliferation. Nrf2 is a 
master regulator of the transcription of many antioxidant 
and detoxification enzymes, which are required to con-
trol the inflammatory process initiated by the detection 
and phagocytosis of malaria [30]. One such enzyme is 
HO-1 (encoded by the Hmox-1 gene), known for its role 
in heme detoxification during malaria by the cataboliza-
tion of free heme into biliverdin, iron and carbon monox-
ide [61]. HO-1 was shown to have protective properties 
in an experimental cerebral malaria model [32, 33]. In 
this manuscript, a correlation between high HO-1 mRNA 
levels in monocytes from MoHBW was established, con-
firming a beneficial role during PAM outcomes. How-
ever, recent data propose that high placental parasitaemia 
leads to an excessive activity of HO-1; intracellular iron 
accumulation and overload in trophoblasts, inducing cell 
death and impairing fetal development [62]. Altogether, 
this suggests that Nrf2 plays a central role in defining the 
balance between pro- and anti-oxidant mechanisms that 
appears essential for both infection elimination and host 
protection.
Conclusions
This work demonstrates the role of the CD36 scavenger 
receptor, the enzyme HO-1 and the anti-oxidant path-
way Nrf2 in protection against the pathology of malaria 
during pregnancy. Whereas the antioxidant and detoxi-
fying effects of Nrf2-dependent HO-1 corroborate with 
other published data, the function of CD36 expression on 
monocytes during PAM needs further clarification. The 
positive association of CD36 in PAM clinical outcomes 
deserves corroboration in other populations and studies, 
including a larger group of mothers with low birth weight 
infants.
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